Current Research Studies

Cancer – REGN2810 in Pediatric Patients with Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed or Recurrent Glioma

Condition or Therapy:

Relapsed or refractory solid tumor, relapsed or refractory central nervous system tumor, DIPG

Category:

Cancer and blood disorders

What is the goal of this study?

The goal of this study is to determine the safety of RP2D for children with recurrent or refractory solid or CNS tumors.

Who can join the study?

This study may be a good fit for children and young adults who:

  • Are up to 25 years old and
  • Have a CNS tumor or DIPG

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.


Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Sarah Leary